Publication highlights Deramiocel’s anti-fibrotic activity and describes a validated potency assay supporting quality control ...
Stocktwits on MSN
Capricor Therapeutics Stock Becomes Talk Of Retail Town On DMD Study; Retail Sees New Hope After Sarepta Setback
Capricor’s peer-reviewed publication in Biomedicines reinforced the scientific foundation of its Duchenne therapy Deramiocel, ...
Capricor Therapeutics (CAPR) announced the publication in Biomedicines, an international peer-reviewed journal, describing a novel in-vitro ...
Capricor Therapeutics (CAPR) announced that the European Medicines Agency, EMA, has granted both Orphan Drug and Advanced Therapy Medicinal Product, ATMP, designations to its lead asset, deramiocel, ...
Capricor Therapeutics saw its shares fall 13% by the end of trading Monday as its investigational cell therapy deramiocel for DMD was revealed as the first drug expected to face an FDA advisory ...
(RTTNews) - Biotechnology company Capricor Therapeutics (CAPR) Thursday announced the completion of the submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration ...
Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the ...
Marban reiterated confidence in regulatory timelines and potential approval, stating, "We aim to have over 100 patients transition from clinical to commercial product following potential BLA approval.
Capricor Therapeutics is advancing deramiocel, an allogeneic cell therapy for DMD-related cardiomyopathy, with a rolling BLA submission and potential FDA approval by 2025. Deramiocel showed ...
SAN DIEGO, June 20, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today ...
Deramiocel-treated patients sees a median decline of only 0.5 points after four years. Fourth-year PUL v2.0 decline (0.6 points) is less than one-third of the first year’s drop. Post-Labor Day Trading ...
In male patients with DMD, treatment with deramiocel reduced upper limb function deterioration compared with placebo. The Food and Drug Administration (FDA) has granted Priority Review to the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback